<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00333775</url>
  </required_header>
  <id_info>
    <org_study_id>BO17708</org_study_id>
    <secondary_id>2005-003862-40</secondary_id>
    <nct_id>NCT00333775</nct_id>
  </id_info>
  <brief_title>A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer</brief_title>
  <official_title>A Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Docetaxel in Comparison With Docetaxel Plus Placebo, as First Line Treatment for Patients With HER2 Negative Metastatic and Locally Recurrent Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of 2 doses of Avastin in combination with
      docetaxel, versus docetaxel plus placebo, in patients with metastatic HER2 negative breast
      cancer who are candidates for taxane-based chemotherapy but who have not received prior
      chemotherapy for metastatic disease. The anticipated time on treatment is 1-2 years and the
      target sample size is 500+ individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Five participants randomized to the docetaxel 100 mg/m^2 plus placebo group actually received
      docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg and are included in the docetaxel 100 mg/m^2
      plus bevacizumab 7.5 mg/kg group for the adverse event results. Sixteen participants
      randomized to the docetaxel 100 mg/m^2 plus placebo group actually received docetaxel 100
      mg/m^2 plus bevacizumab 15.0 mg/kg and are included in the docetaxel 100 mg/m^2 plus
      bevacizumab 15.0 mg/kg group for the adverse event results.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Baseline to the 15 Sep 2008 cut-off date (up to 2 years, 6 months)</time_frame>
    <description>Progression-free survival was evaluated using Response Evaluation Criteria In Solid Tumors (RECIST 1.0). Progression-free survival was defined as the time from randomization to the time of the first documented disease progression or death, whichever occurred first. Disease progression was defined as ≥ 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the unequivocal progression of existing non-target lesions, or appearance of new lesion(s).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Complete Response or a Partial Response</measure>
    <time_frame>Baseline to the 15 Sep 2008 cut-off date (up to 2 years, 6 months)</time_frame>
    <description>Responses were evaluated using the Response Evaluation Criteria in Solid Tumors. A complete response was defined as the disappearance of all target lesions or the disappearance of all non-target lesions and normalization of tumor marker level. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Baseline to the 15 September 2008 cut-off date (up to 2 years, 6 months)</time_frame>
    <description>Duration of response was defined as the time from the first documented complete response or partial response to disease progression or death. A complete response was defined as the disappearance of all target lesions or the disappearance of all non-target lesions and normalization of tumor marker level. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Responses were evaluated using the Response Evaluation Criteria in Solid Tumors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>Baseline to the 15 September 2008 cut-off date (up to 2 years, 6 months)</time_frame>
    <description>Time to treatment failure was defined as time from randomization to the date of disease progression, death, or withdrawal of treatment due to an adverse event, withdrawal of informed consent, insufficient therapeutic response, refusal of treatment/failure to co-operate, or failure to return, whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Baseline to the 15 Sep 2008 cut-off date (up to 2 years, 6 months)</time_frame>
    <description>Overall survival was defined as the time from randomization to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">736</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel 100 mg/m^2 plus placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel was supplied in 2 vials, 1 containing docetaxel and 1 containing a solvent, for intravenous infusion.</description>
    <arm_group_label>Docetaxel 100 mg/m^2 plus placebo</arm_group_label>
    <arm_group_label>Docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg</arm_group_label>
    <arm_group_label>Docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to bevacizumab</intervention_name>
    <description>Placebo to bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.</description>
    <arm_group_label>Docetaxel 100 mg/m^2 plus placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.</description>
    <arm_group_label>Docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg</arm_group_label>
    <arm_group_label>Docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Female patients ≥ 18 years of age.

          -  Human epidermal growth factor receptor 2 (HER2)-negative cancer of the breast with
             locally recurrent or metastatic disease, suitable for chemotherapy.

          -  No adjuvant chemotherapy within 6 months before randomization, and no taxane-based
             chemotherapy within 12 months before randomization.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

        Exclusion criteria:

          -  Previous chemotherapy for metastatic or locally recurrent breast cancer.

          -  Radiotherapy for treatment of metastatic disease.

          -  Other primary tumors within last 5 years, except for controlled limited basal cell or
             squamous cancer of the skin, or cancer in situ of the cervix.

          -  Spinal cord compression or brain metastases.

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to randomization.

          -  Inadequate bone marrow, liver, or renal function.

          -  Uncontrolled hypertension.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <state>New South Wales</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ringwood East</city>
        <state>Victoria</state>
        <zip>3135</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vöcklabruck</city>
        <zip>4840</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <zip>74605-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>31190-131</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florianopolis</city>
        <state>SC</state>
        <zip>88034-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01509-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ansbach</city>
        <zip>91522</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>14195</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lemgo</city>
        <zip>32657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parma</city>
        <state>Emilia-Romagna</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trieste</city>
        <state>Friuli-Venezia Giulia</state>
        <zip>34100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Udine</city>
        <state>Friuli-Venezia Giulia</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Treviglio</city>
        <state>Lombardia</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Macerata</city>
        <state>Marche</state>
        <zip>62100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Biella</city>
        <state>Piemonte</state>
        <zip>13900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taormina</city>
        <state>Sicilia</state>
        <zip>98030</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <zip>08660</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merida</city>
        <zip>97500</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexicali</city>
        <zip>21100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <zip>06760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <zip>64380</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Obregon</city>
        <zip>85000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Puebla</city>
        <zip>72530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sittard</city>
        <zip>6131 BK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Utrecht</city>
        <zip>3582 KE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama City</city>
        <zip>83-0669</zip>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-826</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olsztyn</city>
        <zip>10-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>53-413</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1099-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sandton</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linkoeping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Umea</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <zip>LS16 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middlesex</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Panama</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2006</study_first_submitted>
  <study_first_submitted_qc>June 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2006</study_first_posted>
  <results_first_submitted>July 22, 2015</results_first_submitted>
  <results_first_submitted_qc>December 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2016</results_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>21 participants randomized to the placebo group received bevacizumab 7.5 mg/kg (n=5) or 15.0 mg/kg (n=16). Please see the Detailed Description for an explanation of the differences in the number of participants in the treatment groups in Participant Flow and Adverse Events.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Docetaxel 100 mg/m^2 Plus Placebo</title>
          <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
        </group>
        <group group_id="P2">
          <title>Docetaxel 100 mg/m^2 Plus Bevacizumab 7.5 mg/kg</title>
          <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
        </group>
        <group group_id="P3">
          <title>Docetaxel 100 mg/m^2 Plus Bevacizumab 15.0 mg/kg</title>
          <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="241"/>
                <participants group_id="P2" count="248"/>
                <participants group_id="P3" count="247"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="238"/>
                <participants group_id="P2" count="247"/>
                <participants group_id="P3" count="245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="241"/>
                <participants group_id="P2" count="248"/>
                <participants group_id="P3" count="247"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="149"/>
                <participants group_id="P3" count="143"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>In Follow−up When Study Stopped</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="96"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat population: All randomized participants, regardless of whether they received study drug or not.</population>
      <group_list>
        <group group_id="B1">
          <title>Docetaxel 100 mg/m^2 Plus Placebo</title>
          <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
        </group>
        <group group_id="B2">
          <title>Docetaxel 100 mg/m^2 Plus Bevacizumab 7.5 mg/kg</title>
          <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
        </group>
        <group group_id="B3">
          <title>Docetaxel 100 mg/m^2 Plus Bevacizumab 15.0 mg/kg</title>
          <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="241"/>
            <count group_id="B2" value="248"/>
            <count group_id="B3" value="247"/>
            <count group_id="B4" value="736"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="10.47"/>
                    <measurement group_id="B2" value="53.9" spread="10.61"/>
                    <measurement group_id="B3" value="53.6" spread="10.78"/>
                    <measurement group_id="B4" value="53.7" spread="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="248"/>
                    <measurement group_id="B3" value="247"/>
                    <measurement group_id="B4" value="736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>Progression-free survival was evaluated using Response Evaluation Criteria In Solid Tumors (RECIST 1.0). Progression-free survival was defined as the time from randomization to the time of the first documented disease progression or death, whichever occurred first. Disease progression was defined as ≥ 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the unequivocal progression of existing non-target lesions, or appearance of new lesion(s).</description>
        <time_frame>Baseline to the 15 Sep 2008 cut-off date (up to 2 years, 6 months)</time_frame>
        <population>Intent-to-treat population: All randomized participants, regardless of whether they received study drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel 100 mg/m^2 Plus Placebo</title>
            <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Docetaxel 100 mg/m^2 Plus Bevacizumab 7.5 mg/kg</title>
            <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel 100 mg/m^2 Plus Bevacizumab 15.0 mg/kg</title>
            <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Progression-free survival was evaluated using Response Evaluation Criteria In Solid Tumors (RECIST 1.0). Progression-free survival was defined as the time from randomization to the time of the first documented disease progression or death, whichever occurred first. Disease progression was defined as ≥ 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the unequivocal progression of existing non-target lesions, or appearance of new lesion(s).</description>
          <population>Intent-to-treat population: All randomized participants, regardless of whether they received study drug or not.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="7.2" upper_limit="8.3"/>
                    <measurement group_id="O2" value="8.7" lower_limit="8.2" upper_limit="9.9"/>
                    <measurement group_id="O3" value="8.8" lower_limit="8.4" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0318</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0036</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio, log</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Complete Response or a Partial Response</title>
        <description>Responses were evaluated using the Response Evaluation Criteria in Solid Tumors. A complete response was defined as the disappearance of all target lesions or the disappearance of all non-target lesions and normalization of tumor marker level. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.</description>
        <time_frame>Baseline to the 15 Sep 2008 cut-off date (up to 2 years, 6 months)</time_frame>
        <population>Intent-to-treat population: All randomized participants, regardless of whether they received study drug or not. Only participants with measurable disease at Baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel 100 mg/m^2 Plus Placebo</title>
            <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Docetaxel 100 mg/m^2 Plus Bevacizumab 7.5 mg/kg</title>
            <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel 100 mg/m^2 Plus Bevacizumab 15.0 mg/kg</title>
            <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Complete Response or a Partial Response</title>
          <description>Responses were evaluated using the Response Evaluation Criteria in Solid Tumors. A complete response was defined as the disappearance of all target lesions or the disappearance of all non-target lesions and normalization of tumor marker level. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.</description>
          <population>Intent-to-treat population: All randomized participants, regardless of whether they received study drug or not. Only participants with measurable disease at Baseline were included in the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.1" upper_limit="3.4"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.1" upper_limit="6.4"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0.1" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5" lower_limit="36.6" upper_limit="50.5"/>
                    <measurement group_id="O2" value="52.2" lower_limit="45.1" upper_limit="59.3"/>
                    <measurement group_id="O3" value="62.1" lower_limit="55.1" upper_limit="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of response was defined as the time from the first documented complete response or partial response to disease progression or death. A complete response was defined as the disappearance of all target lesions or the disappearance of all non-target lesions and normalization of tumor marker level. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Responses were evaluated using the Response Evaluation Criteria in Solid Tumors.</description>
        <time_frame>Baseline to the 15 September 2008 cut-off date (up to 2 years, 6 months)</time_frame>
        <population>Intent-to-treat population: All randomized participants, regardless of whether they received study drug or not. Only participants with measurable disease at Baseline who had a complete response or a partial response were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel 100 mg/m^2 Plus Placebo</title>
            <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Docetaxel 100 mg/m^2 Plus Bevacizumab 7.5 mg/kg</title>
            <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel 100 mg/m^2 Plus Bevacizumab 15.0 mg/kg</title>
            <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of response was defined as the time from the first documented complete response or partial response to disease progression or death. A complete response was defined as the disappearance of all target lesions or the disappearance of all non-target lesions and normalization of tumor marker level. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Responses were evaluated using the Response Evaluation Criteria in Solid Tumors.</description>
          <population>Intent-to-treat population: All randomized participants, regardless of whether they received study drug or not. Only participants with measurable disease at Baseline who had a complete response or a partial response were included in the analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="5.8" upper_limit="6.9"/>
                    <measurement group_id="O2" value="7.2" lower_limit="6.4" upper_limit="9.1"/>
                    <measurement group_id="O3" value="7.0" lower_limit="6.4" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure</title>
        <description>Time to treatment failure was defined as time from randomization to the date of disease progression, death, or withdrawal of treatment due to an adverse event, withdrawal of informed consent, insufficient therapeutic response, refusal of treatment/failure to co-operate, or failure to return, whichever occurred first.</description>
        <time_frame>Baseline to the 15 September 2008 cut-off date (up to 2 years, 6 months)</time_frame>
        <population>Intent-to-treat population: All randomized participants, regardless of whether they received study drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel 100 mg/m^2 Plus Placebo</title>
            <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Docetaxel 100 mg/m^2 Plus Bevacizumab 7.5 mg/kg</title>
            <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel 100 mg/m^2 Plus Bevacizumab 15.0 mg/kg</title>
            <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure</title>
          <description>Time to treatment failure was defined as time from randomization to the date of disease progression, death, or withdrawal of treatment due to an adverse event, withdrawal of informed consent, insufficient therapeutic response, refusal of treatment/failure to co-operate, or failure to return, whichever occurred first.</description>
          <population>Intent-to-treat population: All randomized participants, regardless of whether they received study drug or not.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="5.6" upper_limit="7.0"/>
                    <measurement group_id="O2" value="7.0" lower_limit="6.1" upper_limit="7.7"/>
                    <measurement group_id="O3" value="7.7" lower_limit="7.1" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1105</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0241</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival was defined as the time from randomization to death from any cause.</description>
        <time_frame>Baseline to the 15 Sep 2008 cut-off date (up to 2 years, 6 months)</time_frame>
        <population>Intent-to-treat population: All randomized participants, regardless of whether they received study drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel 100 mg/m^2 Plus Placebo</title>
            <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Docetaxel 100 mg/m^2 Plus Bevacizumab 7.5 mg/kg</title>
            <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel 100 mg/m^2 Plus Bevacizumab 15.0 mg/kg</title>
            <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival was defined as the time from randomization to death from any cause.</description>
          <population>Intent-to-treat population: All randomized participants, regardless of whether they received study drug or not.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to the low number of events, the median and lower and upper limits of the 95% confidence interval could not be reliably estimated.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="15.7">Due to the low number of events, the median and upper limit of the 95% confidence interval could not be reliably estimated.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="14.9">Due to the low number of events, the median and upper limit of the 95% confidence interval could not be reliably estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6962</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0765</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety population: All randomized participants exposed to study medication.
Please see the Detailed Description for an explanation of the differences in the number of participants in the treatment groups in Participant Flow and Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Docetaxel 100 mg/m^2 Plus Placebo</title>
          <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
        </group>
        <group group_id="E2">
          <title>Docetaxel 100 mg/m^2 Plus Bevacizumab 7.5 mg/kg</title>
          <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
        </group>
        <group group_id="E3">
          <title>Docetaxel 100 mg/m^2 Plus Bevacizumab 15.0 mg/kg</title>
          <description>Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="120" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Gastroduodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Catheter related complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Ill−defined disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Multi−organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hepatorenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Anal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Catheter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Catheter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Nail bed infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Periodontal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Purulent discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Stent related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Narcotic intoxication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Inflammatory carcinoma of the breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Non−hodgkin’s lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Cranial nerve palsies multiple</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Nasal septum ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Stevens−Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Central venous catheter removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Vertebroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="216" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="251" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="260" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="120" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="143" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="132" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="115" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="88" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="128" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="181" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="183" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Palmar−plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Onycholysis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Nail toxicity</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

